Contamination Control Strategy (CCS) Implementation in Aseptic Biologics Manufacturing
Case Study: Remediation of Aseptic Operations — Oversight, EM, and Sterility Assurance Redesign
10.03.2026
Case Study
Case Study Overview
Sterility assurance remediation in sterile biologics manufacturing is one of the most critical challenges for vaccine and injectable drug producers. When aseptic operations fall short of Annex 1 requirements, the risks extend beyond compliance — threatening patient safety, regulatory approval, and supply continuity. This case study shows how GMP Bridge supported a DACH-based biologics manufacturer to redesign its Contamination Control Strategy (CCS), optimize Environmental Monitoring (EM), and strengthen Quality Oversight, ensuring sustainable compliance and restored client confidence.
The Challenge
A sterile biologics manufacturer in the DACH region faced significant sterility assurance risks after repeated client complaints and regulatory observations. The site’s aseptic operations were considered non-compliant, with gaps in oversight, contamination control, and environmental monitoring practices threatening supply continuity and regulatory trust.
Solution Delivered
To address the client’s sterility assurance and regulatory challenges, GMP Bridge implemented a structured, risk-based program aligned with EU GMP Annex 1. The engagement focused on strengthening contamination control, improving governance of aseptic processes, and establishing sustainable compliance practices.
Impact and Results
The engagement delivered measurable improvements in sterility assurance, regulatory readiness, and operational governance across the manufacturing site.
Inspection Readiness Achieved
The site successfully prepared for the upcoming health authority inspection, restoring regulatory confidence in the sterility assurance framework.
Annex 1 Aligned Contamination Control Strategy
A comprehensive contamination control strategy was fully implemented and made auditable ahead of the scheduled inspection.
Strengthened Sterility Assurance Framework
Contamination control processes across aseptic manufacturing were reinforced to ensure robust and sustainable sterility assurance.
Risk-Based Mitigation of Critical Gaps
Critical risks were systematically addressed through structured risk assessments and targeted action plans.
Enhanced Ownership and Governance Culture
A dedicated quality oversight program strengthened accountability and cross-functional ownership of contamination control activities.
Company Details
- Region: DACH
- Company: Single-site sterile biologics manufacturer
- Products: Vaccines and sterile injectable drug products
Ready to talk the specifics?
So Are we - Get in Touch
- (+49) 174 957 5861
- contact@gmpbridge.com